We have located links that may give you full text access.
Clinical Trial
Letter
Doxycycline for the treatment of cutaneous leishmaniasis.
The incidence of cutaneous leishmaniasis has shown a resurgence in recent years in Tunisia. Because of the toxicity and high cost of pentavalent antimonials we have sought alternative medications. In a study of 14 patients with cutaneous leishmaniasis, ten patients achieved complete clinical regression of the lesions with oral administration of doxycycline, 200mg per day, for 15-30 days.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app